Zymeworks (ZYME) Depreciation & Amortization (CF) (2022 - 2026)
Zymeworks' (ZYME) quarterly Depreciation & Amortization (CF) came in at $963000.0 in Q1 2026, down 1.83% year-on-year from $981000.0 in Q1 2025, and up 7.24% quarter-over-quarter from $898000.0 in Q4 2025.
Zymeworks (ZYME) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Zymeworks has disclosed Depreciation & Amortization (CF) across 5 years of filings, most recently posting $963000.0 for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $963000.0, down 1.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (down 11.12% YoY), and the FY2025 annual result was $3.7 million, down 12.39% from the prior year.
- Depreciation & Amortization (CF) came in at $963000.0 for Q1 2026 at Zymeworks, up from $898000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.4 million in Q3 2023 to a low of $885000.0 in Q2 2025.
- The 5-year median for Depreciation & Amortization (CF) is $1.1 million (2024), against an average of $1.3 million.
- Across the five-year window, Depreciation & Amortization (CF) soared 73.36% in 2023 and sank 56.89% in 2024, its largest moves.
- Zymeworks' Depreciation & Amortization (CF) stood at $1.2 million in 2022, then surged by 33.33% to $1.5 million in 2023, then sank by 35.09% to $997000.0 in 2024, then dropped by 9.93% to $898000.0 in 2025, then increased by 7.24% to $963000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $963000.0 (Q1 2026), $898000.0 (Q4 2025), and $905000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 963,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 963,000.00 |
| Mar 31, 2026 | 963,000.00 |
| Dec 31, 2025 | 898,000.00 |
| Dec 31, 2025 | 898,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Dec 31, 2024 | 997,000.00 |
| Dec 31, 2024 | 997,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Dec 31, 2023 | 1.54 Mn |